Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma

Introduction Neoadjuvant chemotherapy in high‐risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation. Case presentation We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70‐year‐old male was diagnosed with high‐risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen‐deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate‐specific antigen was undetectable on initial follow‐up. Conclusion We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients.